Exhibitors at the CIIE say they have high expectations for the event, as well as for the Chinese market and continued economic opening up.
GUAN HONG, Head of CRM TA & IPA, Novartis China "Novartis has attended all the CIIE in the past 7 years. We really witness the medicines from exhibition finally to public. In 2021 CIIE, we got a cooperation agreement with Hainan Bo'ao, and then we piloted the RWE study before we got approval. Last year, we got a fast approval by NMPA now it's already benefited more than 10,000 patients in China. We really want to bring the fast-approach products and innovative products to China as soon as possible to benefit as many patients as possible."
TOSHINOBU UMETSU, President & CEO, Shiseido China "For this year's CIIE, we looked at the 'mobility space' with autonomous driving, which is often seen as an iconic advanced innovations around the world. We invite visitors to discover more about the cornerstone on which Shiseido's innovations are built – our globally-leading standards in product safety and quality management."
JEAN-CHRISTOPHE POINTEAU, Global Senior Vice President, Pfizer "Pfizer is set to sign a series of MOUs (on the 7th CIIE). The Third Plenum (of The CPC) emphasized the policies on high-quality development for innovation of the biopharmaceutical sector, which includes easing restrictions on foreign investment. So, this environment is extremely positive and extremely encouraging for the multinationals. And that's why Pfizer and other multinationals are extremely confident."
